Millions of people worldwide are living in chronic pain 1 . This pain is often poorly treated and the over-prescription of opioid-based drugs has contributed to an opioid epidemic that is causing significant morbidity and mortality 2 . New pain-killing and non-opioid based medications are hence urgently needed. A powerful way to identify novel human-validated analgesic drug targets is to study rare individuals with intact damage-sensing neurons that present with a congenital pain insensitive phenotype 3, 4 . For example, the study of pain-free individuals from three consanguineous families from northern Pakistan led to the identification of recessive mutations in SCN9A as a cause of painlessness 5 . SCN9A, which encodes the voltage-gated sodium channel, Nav1.7, is highly expressed in damage-sensing neurons and is now a major drug target in the pharmaceutical industry with several pain clinical trials in progress 6 . Likewise, the study of an Italian family in which six affected individuals displayed a pain insensitive phenotype led to the identification of a point mutation in the ZFHX2 transcriptional regulator, a gene also with enriched expression in peripheral sensory neurons 7 .
Recently a new pain insensitivity disorder was reported from studying a female patient (PFS) who carried both a hypomorphic SNP in the fatty-acid amide hydrolase (FAAH) gene and a microdeletion downstream of FAAH in a novel gene called FAAH-OUT 8 . This patient, in addition to being pain insensitive, also presented with additional clinical symptoms including a happy, non-anxious disposition, enhanced wound healing, reduced stress and fear symptoms and mild memory deficits. FAAH is a major catabolic enzyme for a range of bioactive lipids called fatty-acid amides (FAAs) with substrates including anandamide (AEA), palmitoylethanolamide (PEA), oleoylethanolamine (OEA) and N-acyltaurines [9] [10] [11] . The phenotype observed in PFS likely results from elevated levels of these bioactive lipids due to reduced activity of FAAH. Indeed, mass spectrometry analysis of peripheral blood derived from PFS showed significantly raised levels of AEA, OEA and PEA 
Methods

CRISPR/Cas9 plasmids
Plasmids 61591 12 and 106219 13 (Addgene) were modified for the gene editing (SaCas9) and transcriptional repression (dSaCas9-KRAB) CRISPR experiments. For gene editing plasmid 61591, the CMV promoter was replaced with a shorter promoter sequence derived from the housekeeping Eef1a1 gene and the bGH polyadenylation sequence was replaced with a shorter synthetic polyadenylation sequence. gBlocks gene fragments (IDT) were designed to contain a U6 promoter, guide sequence and modified guide scaffold 14 with the design enabling two guide cassettes to be inserted into one plasmid by In-Fusion cloning (Takara).
Guide sequences were designed using the CRISPOR tool 15 for ACTB minus the test gene. Mean and standard errors were performed on the ΔCT data and converted to relative expression levels (2ˆΔCT). Figure 2B ).
Results
Gene editing mimicking the FAAH-OUT microdeletion reduces FAAH expression
CRISPRi at the FAAH-OUT promoter reduces both FAAH-OUT and FAAH expression
CRISPR interference (CRISPRi) enables gene repression through targeting of a nucleasedeficient form of Cas9 (dCas9) fused to a Krüppel-associated box (KRAB) repressor to specific genomic loci 16, 17 . When localised to DNA, dCas9-KRAB recruits a heterochromatinforming complex that causes histone methylation (H3K9 trimethylation) and deacetylation.
This local modification of the epigenome can help to identify promoter and enhancer elements essential for gene expression 17, 18 . A guide sequence (FOP1) was designed to recruit dSaCas9-KRAB to the putative promoter region of FAAH-OUT (Figure 1 
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